Mutant IDH1 and seizures in patients with glioma

Hao Chen, Jonathon Judkins, Cheddhi Thomas, Meijing Wu, Laith Khoury, Carolina G. Benjamin, Donato Pacione, John G. Golfinos, Priya Kumthekar, Farhad Ghamsari, Li Chen, Pamela J Lein, Dane M. Chetkovich, Matija Snuderl, Craig Horbinski

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: Because the d-2-hydroxyglutarate (D2HG) product of mutant isocitrate dehydrogenase 1 (IDH1 mut) is released by tumor cells into the microenvironment and is structurally similar to the excitatory neurotransmitter glutamate, we sought to determine whether IDH1 mut increases the risk of seizures in patients with glioma, and whether D2HG increases the electrical activity of neurons. Methods: Three WHO grade II-IV glioma cohorts from separate institutions (total N = 712) were retrospectively assessed for the presence of preoperative seizures and tumor location, WHO grade, 1p/19q codeletion, and IDH1 mut status. Rat cortical neurons were grown on microelectrode arrays, and their electrical activity was measured before and after treatment with exogenous D2HG, in the presence or absence of the selective NMDA antagonist, AP5. Results: Preoperative seizures were observed in 18%-34% of IDH1 wild-type (IDH1 wt) patients and in 59%-74% of IDH1 mut patients (p < 0.001). Multivariable analysis, including WHO grade, 1p/19q codeletion, and temporal lobe location, showed that IDH1 mut was an independent correlate with seizures (odds ratio 2.5, 95% confidence interval 1.6-3.9, p < 0.001). Exogenous D2HG increased the firing rate of cultured rat cortical neurons 4- to 6-fold, but was completely blocked by AP5. Conclusions: The D2HG product of IDH1 mut may increase neuronal activity by mimicking the activity of glutamate on the NMDA receptor, and IDH1 mut gliomas are more likely to cause seizures in patients. This has rapid translational implications for the personalized management of tumor-associated epilepsy, as targeted IDH1 mut inhibitors may improve antiepileptic therapy in patients with IDH1 mut gliomas.

Original languageEnglish (US)
Pages (from-to)1805-1813
Number of pages9
JournalNeurology
Volume88
Issue number19
DOIs
StatePublished - May 9 2017

Fingerprint

Glioma
Seizures
Neurons
Glutamic Acid
Cellular Microenvironment
Isocitrate Dehydrogenase
Neoplasms
Microelectrodes
N-Methylaspartate
Temporal Lobe
N-Methyl-D-Aspartate Receptors
Anticonvulsants
Neurotransmitter Agents
Epilepsy
Odds Ratio
alpha-hydroxyglutarate
Confidence Intervals
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Chen, H., Judkins, J., Thomas, C., Wu, M., Khoury, L., Benjamin, C. G., ... Horbinski, C. (2017). Mutant IDH1 and seizures in patients with glioma. Neurology, 88(19), 1805-1813. https://doi.org/10.1212/WNL.0000000000003911

Mutant IDH1 and seizures in patients with glioma. / Chen, Hao; Judkins, Jonathon; Thomas, Cheddhi; Wu, Meijing; Khoury, Laith; Benjamin, Carolina G.; Pacione, Donato; Golfinos, John G.; Kumthekar, Priya; Ghamsari, Farhad; Chen, Li; Lein, Pamela J; Chetkovich, Dane M.; Snuderl, Matija; Horbinski, Craig.

In: Neurology, Vol. 88, No. 19, 09.05.2017, p. 1805-1813.

Research output: Contribution to journalArticle

Chen, H, Judkins, J, Thomas, C, Wu, M, Khoury, L, Benjamin, CG, Pacione, D, Golfinos, JG, Kumthekar, P, Ghamsari, F, Chen, L, Lein, PJ, Chetkovich, DM, Snuderl, M & Horbinski, C 2017, 'Mutant IDH1 and seizures in patients with glioma', Neurology, vol. 88, no. 19, pp. 1805-1813. https://doi.org/10.1212/WNL.0000000000003911
Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017 May 9;88(19):1805-1813. https://doi.org/10.1212/WNL.0000000000003911
Chen, Hao ; Judkins, Jonathon ; Thomas, Cheddhi ; Wu, Meijing ; Khoury, Laith ; Benjamin, Carolina G. ; Pacione, Donato ; Golfinos, John G. ; Kumthekar, Priya ; Ghamsari, Farhad ; Chen, Li ; Lein, Pamela J ; Chetkovich, Dane M. ; Snuderl, Matija ; Horbinski, Craig. / Mutant IDH1 and seizures in patients with glioma. In: Neurology. 2017 ; Vol. 88, No. 19. pp. 1805-1813.
@article{c7ce3a70c3714cf5aef4e35dc6c0a6e4,
title = "Mutant IDH1 and seizures in patients with glioma",
abstract = "Objective: Because the d-2-hydroxyglutarate (D2HG) product of mutant isocitrate dehydrogenase 1 (IDH1 mut) is released by tumor cells into the microenvironment and is structurally similar to the excitatory neurotransmitter glutamate, we sought to determine whether IDH1 mut increases the risk of seizures in patients with glioma, and whether D2HG increases the electrical activity of neurons. Methods: Three WHO grade II-IV glioma cohorts from separate institutions (total N = 712) were retrospectively assessed for the presence of preoperative seizures and tumor location, WHO grade, 1p/19q codeletion, and IDH1 mut status. Rat cortical neurons were grown on microelectrode arrays, and their electrical activity was measured before and after treatment with exogenous D2HG, in the presence or absence of the selective NMDA antagonist, AP5. Results: Preoperative seizures were observed in 18{\%}-34{\%} of IDH1 wild-type (IDH1 wt) patients and in 59{\%}-74{\%} of IDH1 mut patients (p < 0.001). Multivariable analysis, including WHO grade, 1p/19q codeletion, and temporal lobe location, showed that IDH1 mut was an independent correlate with seizures (odds ratio 2.5, 95{\%} confidence interval 1.6-3.9, p < 0.001). Exogenous D2HG increased the firing rate of cultured rat cortical neurons 4- to 6-fold, but was completely blocked by AP5. Conclusions: The D2HG product of IDH1 mut may increase neuronal activity by mimicking the activity of glutamate on the NMDA receptor, and IDH1 mut gliomas are more likely to cause seizures in patients. This has rapid translational implications for the personalized management of tumor-associated epilepsy, as targeted IDH1 mut inhibitors may improve antiepileptic therapy in patients with IDH1 mut gliomas.",
author = "Hao Chen and Jonathon Judkins and Cheddhi Thomas and Meijing Wu and Laith Khoury and Benjamin, {Carolina G.} and Donato Pacione and Golfinos, {John G.} and Priya Kumthekar and Farhad Ghamsari and Li Chen and Lein, {Pamela J} and Chetkovich, {Dane M.} and Matija Snuderl and Craig Horbinski",
year = "2017",
month = "5",
day = "9",
doi = "10.1212/WNL.0000000000003911",
language = "English (US)",
volume = "88",
pages = "1805--1813",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

TY - JOUR

T1 - Mutant IDH1 and seizures in patients with glioma

AU - Chen, Hao

AU - Judkins, Jonathon

AU - Thomas, Cheddhi

AU - Wu, Meijing

AU - Khoury, Laith

AU - Benjamin, Carolina G.

AU - Pacione, Donato

AU - Golfinos, John G.

AU - Kumthekar, Priya

AU - Ghamsari, Farhad

AU - Chen, Li

AU - Lein, Pamela J

AU - Chetkovich, Dane M.

AU - Snuderl, Matija

AU - Horbinski, Craig

PY - 2017/5/9

Y1 - 2017/5/9

N2 - Objective: Because the d-2-hydroxyglutarate (D2HG) product of mutant isocitrate dehydrogenase 1 (IDH1 mut) is released by tumor cells into the microenvironment and is structurally similar to the excitatory neurotransmitter glutamate, we sought to determine whether IDH1 mut increases the risk of seizures in patients with glioma, and whether D2HG increases the electrical activity of neurons. Methods: Three WHO grade II-IV glioma cohorts from separate institutions (total N = 712) were retrospectively assessed for the presence of preoperative seizures and tumor location, WHO grade, 1p/19q codeletion, and IDH1 mut status. Rat cortical neurons were grown on microelectrode arrays, and their electrical activity was measured before and after treatment with exogenous D2HG, in the presence or absence of the selective NMDA antagonist, AP5. Results: Preoperative seizures were observed in 18%-34% of IDH1 wild-type (IDH1 wt) patients and in 59%-74% of IDH1 mut patients (p < 0.001). Multivariable analysis, including WHO grade, 1p/19q codeletion, and temporal lobe location, showed that IDH1 mut was an independent correlate with seizures (odds ratio 2.5, 95% confidence interval 1.6-3.9, p < 0.001). Exogenous D2HG increased the firing rate of cultured rat cortical neurons 4- to 6-fold, but was completely blocked by AP5. Conclusions: The D2HG product of IDH1 mut may increase neuronal activity by mimicking the activity of glutamate on the NMDA receptor, and IDH1 mut gliomas are more likely to cause seizures in patients. This has rapid translational implications for the personalized management of tumor-associated epilepsy, as targeted IDH1 mut inhibitors may improve antiepileptic therapy in patients with IDH1 mut gliomas.

AB - Objective: Because the d-2-hydroxyglutarate (D2HG) product of mutant isocitrate dehydrogenase 1 (IDH1 mut) is released by tumor cells into the microenvironment and is structurally similar to the excitatory neurotransmitter glutamate, we sought to determine whether IDH1 mut increases the risk of seizures in patients with glioma, and whether D2HG increases the electrical activity of neurons. Methods: Three WHO grade II-IV glioma cohorts from separate institutions (total N = 712) were retrospectively assessed for the presence of preoperative seizures and tumor location, WHO grade, 1p/19q codeletion, and IDH1 mut status. Rat cortical neurons were grown on microelectrode arrays, and their electrical activity was measured before and after treatment with exogenous D2HG, in the presence or absence of the selective NMDA antagonist, AP5. Results: Preoperative seizures were observed in 18%-34% of IDH1 wild-type (IDH1 wt) patients and in 59%-74% of IDH1 mut patients (p < 0.001). Multivariable analysis, including WHO grade, 1p/19q codeletion, and temporal lobe location, showed that IDH1 mut was an independent correlate with seizures (odds ratio 2.5, 95% confidence interval 1.6-3.9, p < 0.001). Exogenous D2HG increased the firing rate of cultured rat cortical neurons 4- to 6-fold, but was completely blocked by AP5. Conclusions: The D2HG product of IDH1 mut may increase neuronal activity by mimicking the activity of glutamate on the NMDA receptor, and IDH1 mut gliomas are more likely to cause seizures in patients. This has rapid translational implications for the personalized management of tumor-associated epilepsy, as targeted IDH1 mut inhibitors may improve antiepileptic therapy in patients with IDH1 mut gliomas.

UR - http://www.scopus.com/inward/record.url?scp=85019953465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019953465&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000003911

DO - 10.1212/WNL.0000000000003911

M3 - Article

C2 - 28404805

AN - SCOPUS:85019953465

VL - 88

SP - 1805

EP - 1813

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 19

ER -